share_log

Phase 3 Trial of Shanghai Henlius Biotech's Osteoporosis Drug Meets Primary Study Endpoints

Phase 3 Trial of Shanghai Henlius Biotech's Osteoporosis Drug Meets Primary Study Endpoints

上海漢利生物科技骨質疏鬆症藥物的三期試驗達到初步研究終點
MT Newswires ·  04/05 06:53

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論